Benzinga's Top #PreMarket Gainers

shares rose 63.90 percent to $72.00 in pre-market trading following announcement pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditions.

gained 14.40 percent to $7.31 in pre-market trading after dropping 53.53 percent on Friday. Chardan Capital upgraded Amicus Therapeutics from Neutral to Buy

shares climbed 9.81 percent to $47.90 in pre-market trading after the company reported that its board has authorized a $25 million stock repurchase program.

shares rose 4.61 percent to $17.70 in pre-market trading after the company reported that it has received the FDA approval for the SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System.

shares rose 4.24 percent to $26.55 in pre-market trading after Nelson Peltz's Trian Fund Management disclosed a $2.5 billion stake in GE.